Last updated: February 22, 2026
What is the current development status of Sumanirole?
Sumanirole is a selective dopamine D2 receptor agonist initially developed for Parkinson’s disease (PD). Its development by Pfizer has faced setbacks due to limited efficacy in clinical trials and safety concerns. Phase II clinical trials, conducted around 2010, failed to demonstrate meaningful symptomatic benefit. Pfizer suspended further development in 2012. No recent public disclosures indicate ongoing preclinical or clinical efforts.
What are the key clinical trial results and safety findings?
- Phase II Trials: Conducted to evaluate efficacy in PD patients. Results showed minimal symptom improvement compared to placebo.
- Adverse Events: Reports included mild to moderate nausea, dizziness, and hypotension. Serious adverse events were rare but led to discontinuation in some cases.
- Efficacy Markers: No significant differences in Unified Parkinson’s Disease Rating Scale (UPDRS) scores versus placebo.
- Biomarker Data: Limited publicly available data; no conclusive evidence of neuroprotective effects.
Are there any ongoing or planned clinical studies?
No publicly registered clinical trials for Sumanirole exist beyond the early 2010s. Pfizer has not announced plans for revival, and patent status remains uncertain.
What is the patent position?
- Original Patent: Expired around 2015-2018, depending on jurisdictions.
- Potential for New Patent Filings: Likely limited, barring novel formulations, delivery mechanisms, or indications.
- Market Exclusivity: Not expected to be granted for the molecule itself without development activity.
How does Sumanirole compare with other dopamine agonists?
| Drug |
Selectivity |
Indications |
Marketed By |
Approval Status |
| Pramipexole |
D2/D3 |
Parkinson’s, RLS |
Multiple |
Approved |
| Ropinirole |
D2/D3 |
Parkinson’s, RLS |
Multiple |
Approved |
| Rotigotine |
D3, D2, D1 |
Parkinson’s, RLS, Depression |
UCB, Others |
Approved |
| Sumanirole |
D2 selective |
Investigational (PD) |
Pfizer (discontinued) |
No current approval |
Sumanirole’s selectivity for D2 receptors distinguishes it technically but did not translate into clinical advantage over existing options.
What is the market outlook for selective dopamine agents?
- Market Size (2022): Estimated at $4.5 billion globally for dopamine agonists, predominantly in Parkinson’s disease and restless legs syndrome (RLS) segments.
- Growth Projection (2022-2027): Compound annual growth rate (CAGR) around 4.2%.
- Pipeline Activity: Several newer formulations and delivery methods (transdermal, subcutaneous) are under development, but Sumanirole is absent from current pipelines.
What are the barriers to market entry for Sumanirole-like drugs?
- Efficacy Concerns: Past clinical failures fuel skepticism among investors and developers.
- Safety Profile: Soft tissue fibrosis, impulse control disorders, and hallucinations with existing dopamine agonists pose safety challenges.
- Existing Therapies: Market is saturated with proven drugs; new entrants need clear advantages.
What is the projected market potential?
Without recent development activity or demonstrable clinical benefits, Sumanirole’s market potential remains theoretical. If a next-generation, D2-selective agonist exhibits improved safety and efficacy, a new market opportunity could emerge, but current data do not support this.
Key Takeaways
- Sumanirole is a dopamine D2 receptor agonist with limited clinical development history.
- Pfizer's suspension in 2012 followed Phase II trial failures.
- No current clinical trials or active development efforts are publicly known.
- The drug faces significant barriers including efficacy, safety, and market competition.
- Market size for dopamine agonists remains substantial but highly competitive.
FAQs
1. Why was Sumanirole discontinued?
Due to lack of efficacy in Phase II trials and safety concerns, Pfizer ceased development efforts.
2. Are there any patents protecting Sumanirole now?
Likely expired by 2018; no new patents are publicly registered for the molecule itself.
3. Could Sumanirole be revived for new indications?
Unlikely without significant reformulation, added safety features, or novel therapeutic claims, none of which are publicly planned.
4. How does the current market impact potential return?
The dopamine agonist market's growth is steady, but lack of development activity for Sumanirole reduces its commercial prospects.
5. Are there similar drugs in development?
Yes. Several new dopamine receptor agents are in pipeline, but none focus solely on D2 selectivity like Sumanirole.
References
[1] U.S. FDA Drugs Database (2022). Summary of approved dopamine agonists.
[2] MarketsandMarkets (2022). Global Parkinson's Disease Drugs Market by Type.
[3] Pfizer Inc. (2012). Clinical trial disclosures and development status.
[4] ClinicalTrials.gov. List of Sumanirole-related studies.
